Consecutively, CTLs are capable to kill tumor cells by the release of perforins and granzyme B or by a mechanism that involves Fas ligand (FasL, CD95L)-mediated apoptosis of target cells (1, 2). The gene discussed is GZMB; the disease is neoplasm.